A "unifying theory" of chronic fatigue? Researchers map a shared biological thread across long Covid, ME/CFS, and PTSD

A patient sits in yet another waiting room with a stack of folders, each from a different specialist. One reads "long Covid." Another says "ME/CFS," the chronic-fatigue syndrome medicine has struggled to name for decades. A third says "PTSD." Each label comes with its own treatment plan and its own waiting list, and a quiet suggestion that the others are unrelated. A peer-reviewed paper published in September 2026 in the Journal of Translational Medicine argues those folders belong in the same cabinet.

The paper, led by Prof Dmitry Pshezhetskiy at the University of East Anglia's Norwich Medical School with the commercial 3D-genomics firm Oxford BioDynamics, reports a shared 3D-genome signature across five very different diagnoses: long Covid, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), post-traumatic stress disorder (PTSD), rheumatoid arthritis, and multiple sclerosis. The platform behind the dataset, Oxford BioDynamics' EpiSwitch, looks at how DNA is folded inside cells rather than the linear sequence of genetic letters. The team paired those 3D maps with genome-wide association data, which links specific genetic variants to disease risk in large populations, and standard protein-interaction networks for each condition. That integration is what lets the analysis point at coding genes rather than floating non-coding regions.

The same gene can be read in different ways depending on how the strand is looped and packed inside the cell, so two people with identical genetic letters can end up with very different conditions. A region that is closed off in one cell type and open in another can be the difference between an active immune response and a quiet one. The 3D maps in the paper are the team's bet that this packaging, more than any single mutation, is where the convergence sits.

Across all five conditions, the same symptom cluster keeps showing up: overwhelming fatigue, brain fog, poor concentration, disturbed sleep, autonomic dysfunction, and a dramatic drop in everyday functioning. The authors argue this is not five unrelated bodies happening to feel the same kind of tired; it is the same final common pathway, reachable from many directions, with the shared folding pattern as the substrate underneath.

Prof Pshezhetskiy calls the finding "something approaching a biological unifying theory of fatigue." The word "approaching" is doing the calibration. This is one peer-reviewed paper, not a consensus statement. The team has generated disease-specific 3D-genomic anchor datasets for each condition and mapped them to coding genes, and the analysis is the kind of systems-biology work that needs replication in independent labs. None of the platforms in question is a clinical diagnostic yet, and the press material's hints about future blood tests and shared treatment targets are horizon, not roadmap.

The cohort sizes, statistical thresholds, and replication status reported in the full paper are not visible in the press summary, which means any effect-size claim from this draft would be guessing. Oxford BioDynamics built and operates the platform that produced the dataset; that is not a disqualifying conflict, but it is a reason for an independent lab to repeat the work before anyone calls it a diagnostic roadmap. Patient communities in long Covid and ME/CFS have been promised breakthroughs before, and learned to read them as weather rather than climate.

If the 3D-genome signature holds in independent cohorts, the next decade of research can stop asking which of the five diseases "really" causes the exhaustion and start asking how the same folding pattern is perturbed in each one. A blood test that reads the convergence, and treatments aimed at the pattern rather than the labels, would be on a credible map. For patients who have spent years in three or four different waiting rooms, each one treating a different folder's label, the possibility of a single signature that explains all five is something they do not have now.

The next dataset to watch is whether an independent group outside Oxford BioDynamics and UEA reproduces the convergence in fresh cohorts, and whether the 3D anchors hold up in non-European populations. Both answers can arrive in 2027 if the field treats the paper as a hypothesis to test, not a conclusion to cite.